Microorganisms-derived antigens for preventive anti-cancer vaccines

被引:7
|
作者
Buonaguro, Luigi [1 ]
Cavalluzzo, Beatrice [1 ]
Mauriello, Angela [1 ]
Ragone, Concetta [1 ]
Tornesello, Anna Lucia [2 ]
Buonaguro, Franco M. [2 ]
Tornesello, Maria Lina [2 ]
Tagliamonte, Maria [1 ,3 ]
机构
[1] Ist Nazl Tumori IRCCS Fond G Pascale, Innovat Immunol Models Unit, Naples, Italy
[2] Ist Nazl Tumori IRCCS Fond G Pascale, Mol Biol & Viral Oncogenesis Unit, Naples, Italy
[3] Ist Nazl Studio & Cura Tumori, Fdn Pascale IRCCS, Lab Innovat Immunol Models, Via Mariano Semmola, 52, Naples, Italy
关键词
HEPATITIS-C VIRUS; ENVELOPE GLYCOPROTEIN GP340; CELLULAR IMMUNE-RESPONSES; HUMAN-PAPILLOMAVIRUS VACCINE; CD8(+) T-CELLS; PHASE-I TRIAL; B-VACCINE; COTTONTOP TAMARINS; HEPATOCELLULAR-CARCINOMA; RHESUS MACAQUES;
D O I
10.1016/j.mam.2023.101192
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer prevention is one of the aim with the highest priority in order to reduce the burden of cancer diagnosis and treatment on individuals as well as on healthcare systems.To this aim, vaccines represent the most efficient primary cancer prevention strategy. Indeed, anti-cancer immunological memory elicited by preventive vaccines might promptly expand and prevent tumor from progressing.Antigens derived from microorganisms (MoAs), represent the obvious target for developing highly effective preventive vaccines for virus-induced cancers. In this respect, the drastic reduction in cancer incidence following HBV and HPV preventive vaccines are the paradigmatic example of such evidence. More recently, experimental evidences suggest that MoAs may represent a "natural" anti-cancer preventive vaccination or can be exploited for developing vaccines to prevent cancers presenting highly homologous tumor-associated antigens (TAAs) (e.g. molecular mimicry).The present review describes the different preventive anti-cancer vaccines based on antigens derived from pathogens at the different stages of development.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Anti-cancer therapeutic vaccines
    Lantz, Olivier
    Girard, Nicolas
    Vivier, Eric
    Miossec, Pierre
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2024, 208 (09): : 1254 - 1257
  • [2] Human tumour antigens recognized by T cells: New perspectives for anti-cancer vaccines?
    Coulie, PG
    MOLECULAR MEDICINE TODAY, 1997, 3 (06): : 261 - 268
  • [3] Glycan changes: cancer metastasis and anti-cancer vaccines
    Li, Min
    Song, Lujun
    Qin, Xinyu
    JOURNAL OF BIOSCIENCES, 2010, 35 (04) : 665 - 673
  • [4] Glycan changes: cancer metastasis and anti-cancer vaccines
    Min Li
    Lujun Song
    Xinyu Qin
    Journal of Biosciences, 2010, 35 : 665 - 673
  • [5] Production of Recombinant Anti-Cancer Vaccines in Plants
    Lee, Jeong Hwan
    Ko, Kisung
    BIOMOLECULES & THERAPEUTICS, 2017, 25 (04) : 345 - 353
  • [6] Radiation and Anti-Cancer Vaccines: A Winning Combination
    Cadena, Alexandra
    Cushman, Taylor R.
    Anderson, Clark
    Barsoumian, Hampartsoum B.
    Welsh, JamesW.
    Cortez, Maria Angelica
    VACCINES, 2018, 6 (01):
  • [7] Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization
    Ragone, Concetta
    Mauriello, Angela
    Cavalluzzo, Beatrice
    Cavalcanti, Ernesta
    Russo, Luigi
    Manolio, Carmen
    Mangano, Simona
    Cembrola, Biancamaria
    Tagliamonte, Maria
    Buonaguro, Luigi
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [8] Tumor-associated carbohydrate antigens defining tumor malignancy: Basis for development of anti-cancer vaccines
    Hakomori, S
    MOLECULAR IMMUNOLOGY OF COMPLEX CARBOHYDRATES-2, 2001, 491 : 369 - 402
  • [9] Anti-cancer telomerase vaccines are entering the age of maturity
    Filaci, G.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 37 - 37
  • [10] Advances and challenges in anti-cancer vaccines for multiple myeloma
    Abdollahi, Pegah
    Norseth, Hanne Marie
    Schjesvold, Fredrik
    FRONTIERS IN IMMUNOLOGY, 2024, 15